SCL and ACIU made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 30, 2026.

AC Immune NASDAQ: ACIU reported results from Part 1 of its VacSYn Phase II trial evaluating ACI-7104

AC Immune maintains a "Buy" rating, driven by positive 100-week safety and immunogenicity data for A

AC Immune reported positive safety and immunogenicity results from Part 1 of its Phase 2 Parkinson&#

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company developing targeted therapeut

All primary endpoints of the study were met, with ACI-7104 shown to be generally safe and well toler

Gainers VolitionRX (AMEX:VNRX) shares increased by 102.2% to $0.69 during Thursday's pre-market

AC Immune reports favorable interim Phase 1 results for ACI-19764, an oral NLRP3 inhibitor showing s

AC Immune announced positive interim Phase 1 results from a first-in-human clinical study evaluating

AC Immune (ACIU) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Es

AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly-owned programs

Across these AAIC presentations, we are showing how AC Immune’s Morphomer®-based small molecule appr

AC Immune to Showcase Neurodegenerative Disease Pipeline with Three Presentations at AAIC ® 2026 Lau

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeu

AC Immune Reports Interim 12-Month Data from Phase 1b/2 ABATE Trial of ACI-24 in Prodromal Alzheimer

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeu

AC Immune to Receive Research Grant from Goradia Family for Development of ACI-7104 in Parkinson's D

AC Immune (ACIU) witnesses a hammer chart pattern, indicating support found by the stock after losin

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patie

AC Immune Presents New Phase 1 Data Indicating Higher Uptake of TDP-43 PET Tracer ACI-19626 in Patie

Davos Alzheimer's Collaborative Celebrates Andrea Pfeifer, Retiring CEO of AC Immune, for Her Contri

AC Immune (ACIU) appears to have found support after losing some value lately, as indicated by the f

AC Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM Co-founder and CEO, Dr Andre

AC Immune (ACIU) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estima

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.19) per share which beat the analyst consen

As a result, AC Immune will receive a $12 million milestone payment from Takeda under the partners&#

AC Immune First Quarter 2026 Financial and Corporate Updates Dosed first subjects in Phase 1 trial o

AC Immune Initiates Final Cohort in Ongoing Phase 1b/2 ABATE Trial of Anti-Abeta Active Immunotherap

Dow futures down 0.1%. FGI Industries (NASDAQ: FGI) reported mixed results for Q4, with losses of 29

AC Immune stock gains after expansion of its agreement with LLY, adding next-generation Tau Morphome

Here is how AC Immune (ACIU) and Assertio (ASRT) have performed compared to their sector so far this

Under this amendment, AC Immune will receive a CHF10 million upfront payment and a subsequent milest

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.17) per share which beat the analyst consen

ACI-19764 is an orally available highly brain-penetrant small molecule NLRP3 inhibitorNLRP3 inhibito

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeu

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.20) per share which beat the analyst consen

AC Immune SA (NASDAQ:ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeu

AC Immune (NASDAQ:ACIU) reported quarterly losses of $(0.21) per share which missed the analyst cons

https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzh

Companies Reporting Before The Bell • KVH Industries (NASDAQ:KVHI) is projected to report quarterly

Gainers Advent Technologies Holdings, Inc. (NYSE: ADN) shares surged 244% to close at $3.99 on Th

  On Wednesday, 807 companies reached new 52-week lows.

  On Friday, 1043 companies hit new 52-week lows.

  During Thursday, 849 stocks hit new 52-week lows.